HCW Biologics Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 30 Jun 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 01 Jun 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 02 Mar 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Past financial statements no longer reliable (8-K Item 4.02)
The company stated in a Form 8-K (Item 4.02) filed on 14 Aug 2026 that previously issued financial statements should no longer be relied upon. This usually leads to a restatement of past results.
More details →HCW Biologics Inc. — Overview & Financial Snapshot
HCW Biologics Inc. (NasdaqCM: HCWB) is a Healthcare company, ranked #3,355 of 6,774 companies globally and #1,409 of 4,000 in United States on PositoAI, with a Positivity Score of 20,638. Its market capitalisation is ₹23.64 Cr ($2.50M), P/E ratio is -0.1 and P/B ratio is 0.34. It currently has 3 active red flags (PosiRed) and 1 yellow flag (PosiYellow, 6/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →